Development of Processes for Recombinant L-Asparaginase II Production by <i>Escherichia coli</i> Bl21 (De3): From Shaker to Bioreactors
Since 1961, L-asparaginase has been used to treat patients with acute lymphocytic leukemia. It rapidly depletes the plasma asparagine and deprives the blood cells of this circulating amino acid, essential for the metabolic cycles of cells. In the search for viable alternatives to produce L-asparagin...
Saved in:
Main Authors: | Thaís Barros (Author), Larissa Brumano (Author), Marcela Freitas (Author), Adalberto Pessoa (Author), Nádia Parachin (Author), Pérola O. Magalhães (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2020-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
L-Asparaginase from <i>Penicillium sizovae</i> Produced by a Recombinant <i>Komagataella phaffii</i> Strain
by: Marcela Freitas, et al.
Published: (2022) -
Expression and Biological Evaluation of an Engineered Recombinant L-asparaginase Designed by In Silico Method Based on Sequence of the Enzyme from Escherichia coli
by: Mahrokh Dastmalchi, et al.
Published: (2023) -
Activity and Effectiveness of Recombinant hEGF Excreted by Escherichia coli BL21 on Wound Healing in Induced Diabetic Mice
by: Sriwidodo S, et al.
Published: (2020) -
Purity of maltose-binding protein - Recombinant streptavidin expressed in Escherichia coli BL21 (pD861-MBP: 327892)
by: Toto Subroto, et al.
Published: (2022) -
<i>Escherichia coli</i> Recent Advances on Physiology, Pathogenesis and Biotechnological Applications
Published: (2017)